XELJANZ® (tofacitinib citrate)
Patient Adherence Program
PROGRAM OVERVIEW
This sponsored program aims to provide education and support to patients prescribed XELJANZ for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
The program consists of a series of 12 messages delivered over 9 months, with information and topics focused on the quality use of medicines and improving medication adherence and treatment outcomes for patients.
WHEN?
This program launched June 19, 2024.
FOR WHICH PATIENTS?
Messages will be delivered via the app to patients currently prescribed XELJANZ for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.